+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Long-acting Somatostatin Analogues Market - Global Forecast 2026-2032- Product Image
Long-acting Somatostatin Analogues Market - Global Forecast 2026-2032- Product Image
Sale

Long-acting Somatostatin Analogues Market - Global Forecast 2026-2032

  • Report

  • 190 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6117597
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Long-acting Somatostatin Analogues Market is projected to reach USD 4.06 Billion in 2026. It is expected to continue growing at a CAGR of 11.55%, reaching USD 7.85 Billion by 2032.

Long-Acting Somatostatin Analogues: Executive Summary

Long-acting somatostatin analogues are depot formulations used primarily to manage hormone-secreting neuroendocrine tumors and disorders associated with excess growth hormone. Their clinical value rests on sustained receptor-mediated suppression of hormone release, reduced administration frequency, and the potential to support continuity of care. Market development is shaped by disease recognition, specialist access, diagnostic capacity, reimbursement, formulation innovation, and monitoring requirements.

Care Delivery Is Shifting Toward Durable, Specialist-Guided Treatment

The treatment landscape is moving from episodic symptom control toward longitudinal disease management. Longer dosing intervals can reduce injection burden and may help align therapy with outpatient workflows, although administration technique, storage, adherence, and follow-up remain important. Greater use of multidisciplinary care is also connecting endocrinology, oncology, gastroenterology, nuclear medicine, surgery, pharmacy, and nursing services.

Clinical decision-making increasingly depends on biochemical monitoring, imaging, tumor grade, receptor status, comorbidities, and patient preference. Access remains uneven because diagnosis may be delayed, specialist services are concentrated in major centers, and reimbursement policies differ substantially across health systems.

Artificial Intelligence Can Strengthen Diagnosis, Monitoring, and Operational Coordination

Artificial intelligence can contribute to earlier identification of suspected acromegaly or neuroendocrine tumors by supporting analysis of laboratory patterns, imaging, pathology, and clinical documentation. In established disease, machine-learning tools may assist with risk stratification, treatment-response assessment, adverse-event surveillance, and identification of patients needing reassessment.

The most credible near-term value is decision support rather than autonomous treatment selection. Effective implementation requires representative data, transparent validation, clinician oversight, privacy safeguards, and integration with electronic health records. AI may also improve appointment planning, medication logistics, and follow-up prioritization, but bias, explainability, interoperability, and regulatory accountability remain material constraints.

Regional Insights: Access, Diagnosis, and Reimbursement Define Adoption Conditions

North America benefits from advanced specialty care, established diagnostic pathways, and broad access to complex medicines, while affordability, prior authorization, and disparities between care settings can influence treatment continuity. Latin America shows meaningful clinical need but uneven specialist coverage, diagnostic infrastructure, procurement capacity, and reimbursement, making referral networks and reliable supply especially important.

Europe combines strong clinical expertise with country-specific assessment, pricing, and reimbursement processes. The Middle East is expanding specialist capabilities in selected urban centers, although access can vary by country and payer. Africa faces pronounced gaps in diagnosis, specialist availability, cold-chain reliability, and financing, with regional centers and task-appropriate training offering practical avenues for improvement. Asia-Pacific is highly diverse: Japan, Australia, South Korea, China, India, and Southeast Asian systems differ in regulatory pathways, reimbursement, urban concentration, and treatment capacity.

Group Insights: Economic and Alliance Structures Shape Health-System Readiness

ASEAN markets are characterized by varied regulatory maturity, healthcare financing, and specialist distribution; collaboration on procurement, training, and referral pathways can help address fragmentation. BRICS members span substantial differences in public-sector capacity, domestic manufacturing, reimbursement, and access to advanced diagnostics, so strategies must be adapted to national conditions rather than treated as a single bloc.

The European Union benefits from shared scientific and regulatory cooperation, but national reimbursement and service organization remain decisive. G7 systems generally have strong specialty infrastructure and pharmacovigilance capabilities, while still confronting affordability, administrative burden, and unequal access. GCC countries often possess well-resourced tertiary facilities and are investing in specialist services, yet workforce concentration and reliance on centralized care remain relevant. NATO members represent diverse health systems; defense or alliance membership does not imply uniform medicine access, and civilian reimbursement and clinical capacity remain the determining factors.

Country Insights: National Systems Require Tailored Access Strategies

Australia and Canada combine advanced specialist care with geographic dispersion that can complicate access outside major cities. Brazil and Mexico face regional variation in public and private provision, while referral coordination and diagnostic availability remain important. China is strengthening oncology and endocrine capabilities across a broad health system, with access shaped by provincial implementation and reimbursement. India’s large and diverse population creates substantial need alongside uneven specialist and diagnostic coverage.

France, Germany, Italy, Spain, and the United Kingdom have established specialist pathways, but procurement, assessment, reimbursement, and service organization differ across their systems. Japan and South Korea have sophisticated healthcare infrastructure and aging populations, with regulatory and clinical practice requirements influencing uptake. Russia’s access environment is affected by regional distribution, procurement, and broader health-system constraints. Across these countries, sustained outcomes depend on timely diagnosis, reliable supply, trained providers, patient monitoring, and equitable reimbursement.

Action Priorities for Leaders: Improve Diagnosis, Continuity, and Evidence Quality

Industry leaders should prioritize partnerships that expand referral pathways, laboratory capacity, imaging access, and clinician education, particularly outside major metropolitan centers. Patient-support models should reduce missed administrations while respecting privacy, local practice, and the role of healthcare professionals. Supply planning should address formulation availability, storage, administration scheduling, and contingency arrangements.

Evidence generation should focus on real-world persistence, quality of life, biochemical control, tumor outcomes where relevant, safety, and health-system utilization. Decision makers should use transparent comparative evidence and budget-impact analyses without assuming that clinical benefit automatically translates into system value. Digital tools, including AI, should be deployed through governed pilots with measurable outcomes, human review, cybersecurity controls, and clear accountability.

Research Methodology: Evidence-Led Analysis of Clinical and Health-System Drivers

This executive summary uses a structured market-analysis framework focused on the clinical role and access environment for long-acting somatostatin analogues. Assessment dimensions include disease burden and diagnosis, treatment practice, formulation characteristics, specialist infrastructure, reimbursement, regulation, supply considerations, patient continuity, and regional health-system conditions.

Insights should be validated against peer-reviewed clinical literature, regulatory and health-technology-assessment publications, treatment guidelines, public health data, procurement information, and documented healthcare-system policies. Regional, group, and country comparisons are interpretive and account for heterogeneity in epidemiology, service delivery, financing, and data quality. No unsupported quantitative market estimates, shares, or forecasts are used.

Conclusion: Sustainable Value Depends on Integrated, Equitable Disease Management

Long-acting somatostatin analogues occupy an important role in chronic management of selected endocrine and neuroendocrine conditions, but their impact depends on more than pharmacology. Earlier diagnosis, specialist coordination, appropriate monitoring, dependable supply, and affordable access determine whether patients can maintain effective treatment over time.

The strongest opportunities lie in strengthening care pathways, reducing avoidable treatment friction, and applying evidence and technology responsibly. Strategies that reflect national differences while preserving clinical quality will be better positioned to improve continuity, patient outcomes, and health-system efficiency.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Long-acting Somatostatin Analogues Market, by Product Type
7.1. Introduction
7.2. Lanreotide Autogel
7.3. Octreotide LAR
7.4. Pasireotide LAR
8. Long-acting Somatostatin Analogues Market, by Indication
8.1. Introduction
8.2. Acromegaly
8.3. Cushing's Disease
8.4. Neuroendocrine Tumors
8.4.1. Gastroenteropancreatic NETs
8.4.2. Pulmonary NETs
9. Long-acting Somatostatin Analogues Market, by Route Of Administration
9.1. Introduction
9.2. Deep Subcutaneous Injection
9.3. Intramuscular Injection
10. Long-acting Somatostatin Analogues Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Mail Order Pharmacies
10.4. Retail Pharmacies
11. Long-acting Somatostatin Analogues Market, by Patient Age Group
11.1. Introduction
11.2. Adult
11.3. Pediatric
12. Long-acting Somatostatin Analogues Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Long-acting Somatostatin Analogues Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Long-acting Somatostatin Analogues Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Amneal Pharmaceuticals, Inc.
16.2. Bachem Holding AG
16.3. BioSynthema Inc.
16.4. Camurus AB
16.5. Chengdu Tiantaishan Pharmaceutical Co., Ltd.
16.6. Chiasma, Inc.
16.7. Cipla Limited
16.8. Crinetics Pharmaceuticals, Inc.
16.9. Dauntless Pharmaceuticals, Inc.
16.10. Debiopharm Group
16.11. EVER Pharma GmbH
16.12. Ferring Pharmaceuticals
16.13. Ipsen Pharma
16.14. Midatech Pharma PLC
16.15. Mylan N.V.
16.16. Novartis AG
16.17. Peptron Inc.
16.18. Pfizer Inc.
16.19. Recordati S.p.A.
16.20. Sandoz International GmbH
16.21. ScinoPharm Taiwan Ltd.
16.22. Sun Pharmaceutical Industries Ltd.
16.23. Teva Pharmaceutical Industries Ltd.
16.24. Wockhardt Ltd.
16.25. Zydus Lifesciences Limited
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Long-acting Somatostatin Analogues Market, Years Considered for the Study
FIGURE 2. Global Long-acting Somatostatin Analogues Market, Research Design
FIGURE 3. Global Long-acting Somatostatin Analogues Market, Research Framework
FIGURE 4. Global Long-acting Somatostatin Analogues Market, Data Triangulation
FIGURE 5. Global Long-acting Somatostatin Analogues Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Long-acting Somatostatin Analogues Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 7. Global Long-acting Somatostatin Analogues Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Long-acting Somatostatin Analogues Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 9. Global Long-acting Somatostatin Analogues Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Long-acting Somatostatin Analogues Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 11. Global Long-acting Somatostatin Analogues Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Long-acting Somatostatin Analogues Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 13. Global Long-acting Somatostatin Analogues Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Long-acting Somatostatin Analogues Market Size, by Patient Age Group, 2025 vs 2032 (%)
FIGURE 15. Global Long-acting Somatostatin Analogues Market Size, by Patient Age Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Long-acting Somatostatin Analogues Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Long-acting Somatostatin Analogues Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Long-acting Somatostatin Analogues Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Long-acting Somatostatin Analogues Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Long-acting Somatostatin Analogues Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Long-acting Somatostatin Analogues Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Long-acting Somatostatin Analogues Market Segmentation & Coverage
TABLE 2. Global Long-acting Somatostatin Analogues Market Size, 2017-2032 (USD Million)
TABLE 3. Global Long-acting Somatostatin Analogues Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 4. Global Lanreotide Autogel Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Lanreotide Autogel Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Lanreotide Autogel Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Octreotide LAR Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Octreotide LAR Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Octreotide LAR Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Pasireotide LAR Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Pasireotide LAR Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Pasireotide LAR Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Long-acting Somatostatin Analogues Market Size, by Indication, 2017-2032 (USD Million)
TABLE 14. Global Acromegaly Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Acromegaly Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Acromegaly Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Cushing's Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Cushing's Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Cushing's Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Neuroendocrine Tumors Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Neuroendocrine Tumors Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Neuroendocrine Tumors Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Gastroenteropancreatic NETs Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Gastroenteropancreatic NETs Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Gastroenteropancreatic NETs Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Pulmonary NETs Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Pulmonary NETs Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Pulmonary NETs Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Long-acting Somatostatin Analogues Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 30. Global Deep Subcutaneous Injection Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global Deep Subcutaneous Injection Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global Deep Subcutaneous Injection Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global Intramuscular Injection Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Intramuscular Injection Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Intramuscular Injection Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Long-acting Somatostatin Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 37. Global Hospital Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Hospital Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Hospital Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Mail Order Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Mail Order Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Mail Order Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Long-acting Somatostatin Analogues Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 47. Global Adult Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Adult Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Adult Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Long-acting Somatostatin Analogues Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Asia-Pacific Long-acting Somatostatin Analogues Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Asia-Pacific Long-acting Somatostatin Analogues Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 56. Asia-Pacific Long-acting Somatostatin Analogues Market Size, by Indication, 2017-2032 (USD Million)
TABLE 57. Asia-Pacific Long-acting Somatostatin Analogues Market Size, by Neuroendocrine Tumors, 2017-2032 (USD Million)
TABLE 58. Asia-Pacific Long-acting Somatostatin Analogues Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 59. Asia-Pacific Long-acting Somatostatin Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 60. Asia-Pacific Long-acting Somatostatin Analogues Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 61. North America Long-acting Somatostatin Analogues Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. North America Long-acting Somatostatin Analogues Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 63. North America Long-acting Somatostatin Analogues Market Size, by Indication, 2017-2032 (USD Million)
TABLE 64. North America Long-acting Somatostatin Analogues Market Size, by Neuroendocrine Tumors, 2017-2032 (USD Million)
TABLE 65. North America Long-acting Somatostatin Analogues Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 66. North America Long-acting Somatostatin Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 67. North America Long-acting Somatostatin Analogues Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 68. Latin America Long-acting Somatostatin Analogues Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Latin America Long-acting Somatostatin Analogues Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 70. Latin America Long-acting Somatostatin Analogues Market Size, by Indication, 2017-2032 (USD Million)
TABLE 71. Latin America Long-acting Somatostatin Analogues Market Size, by Neuroendocrine Tumors, 2017-2032 (USD Million)
TABLE 72. Latin America Long-acting Somatostatin Analogues Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 73. Latin America Long-acting Somatostatin Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 74. Latin America Long-acting Somatostatin Analogues Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 75. Europe Long-acting Somatostatin Analogues Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Europe Long-acting Somatostatin Analogues Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 77. Europe Long-acting Somatostatin Analogues Market Size, by Indication, 2017-2032 (USD Million)
TABLE 78. Europe Long-acting Somatostatin Analogues Market Size, by Neuroendocrine Tumors, 2017-2032 (USD Million)
TABLE 79. Europe Long-acting Somatostatin Analogues Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 80. Europe Long-acting Somatostatin Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 81. Europe Long-acting Somatostatin Analogues Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 82. Middle East Long-acting Somatostatin Analogues Market Size, by Region, 2017-2032 (USD Million)
TABLE 83. Middle East Long-acting Somatostatin Analogues Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 84. Middle East Long-acting Somatostatin Analogues Market Size, by Indication, 2017-2032 (USD Million)
TABLE 85. Middle East Long-acting Somatostatin Analogues Market Size, by Neuroendocrine Tumors, 2017-2032 (USD Million)
TABLE 86. Middle East Long-acting Somatostatin Analogues Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 87. Middle East Long-acting Somatostatin Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 88. Middle East Long-acting Somatostatin Analogues Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 89. Africa Long-acting Somatostatin Analogues Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Africa Long-acting Somatostatin Analogues Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 91. Africa Long-acting Somatostatin Analogues Market Size, by Indication, 2017-2032 (USD Million)
TABLE 92. Africa Long-acting Somatostatin Analogues Market Size, by Neuroendocrine Tumors, 2017-2032 (USD Million)
TABLE 93. Africa Long-acting Somatostatin Analogues Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 94. Africa Long-acting Somatostatin Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 95. Africa Long-acting Somatostatin Analogues Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 96. Global Long-acting Somatostatin Analogues Market Size, by Group, 2017-2032 (USD Million)
TABLE 97. ASEAN Long-acting Somatostatin Analogues Market Size, by Group, 2017-2032 (USD Million)
TABLE 98. ASEAN Long-acting Somatostatin Analogues Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 99. ASEAN Long-acting Somatostatin Analogues Market Size, by Indication, 2017-2032 (USD Million)
TABLE 100. ASEAN Long-acting Somatostatin Analogues Market Size, by Neuroendocrine Tumors, 2017-2032 (USD Million)
TABLE 101. ASEAN Long-acting Somatostatin Analogues Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 102. ASEAN Long-acting Somatostatin Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 103. ASEAN Long-acting Somatostatin Analogues Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 104. GCC Long-acting Somatostatin Analogues Market Size, by Group, 2017-2032 (USD Million)
TABLE 105. GCC Long-acting Somatostatin Analogues Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 106. GCC Long-acting Somatostatin Analogues Market Size, by Indication, 2017-2032 (USD Million)
TABLE 107. GCC Long-acting Somatostatin Analogues Market Size, by Neuroendocrine Tumors, 2017-2032 (USD Million)
TABLE 108. GCC Long-acting Somatostatin Analogues Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 109. GCC Long-acting Somatostatin Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 110. GCC Long-acting Somatostatin Analogues Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 111. European Union Long-acting Somatostatin Analogues Market Size, by Group, 2017-2032 (USD Million)
TABLE 112. European Union Long-acting Somatostatin Analogues Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 113. European Union Long-acting Somatostatin Analogues Market Size, by Indication, 2017-2032 (USD Million)
TABLE 114. European Union Long-acting Somatostatin Analogues Market Size, by Neuroendocrine Tumors, 2017-2032 (USD Million)
TABLE 115. European Union Long-acting Somatostatin Analogues Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 116. European Union Long-acting Somatostatin Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 117. European Union Long-acting Somatostatin Analogues Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 118. BRICS Long-acting Somatostatin Analogues Market Size, by Group, 2017-2032 (USD Million)
TABLE 119. BRICS Long-acting Somatostatin Analogues Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 120. BRICS Long-acting Somatostatin Analogues Market Size, by Indication, 2017-2032 (USD Million)
TABLE 121. BRICS Long-acting Somatostatin Analogues Market Size, by Neuroendocrine Tumors, 2017-2032 (USD Million)
TABLE 122. BRICS Long-acting Somatostatin Analogues Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 123. BRICS Long-acting Somatostatin Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 124. BRICS Long-acting Somatostatin Analogues Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 125. G7 Long-acting Somatostatin Analogues Market Size, by Group, 2017-2032 (USD Million)
TABLE 126. G7 Long-acting Somatostatin Analogues Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 127. G7 Long-acting Somatostatin Analogues Market Size, by Indication, 2017-2032 (USD Million)
TABLE 128. G7 Long-acting Somatostatin Analogues Market Size, by Neuroendocrine Tumors, 2017-2032 (USD Million)
TABLE 129. G7 Long-acting Somatostatin Analogues Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 130. G7 Long-acting Somatostatin Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 131. G7 Long-acting Somatostatin Analogues Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 132. NATO Long-acting Somatostatin Analogues Market Size, by Group, 2017-2032 (USD Million)
TABLE 133. NATO Long-acting Somatostatin Analogues Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 134. NATO Long-acting Somatostatin Analogues Market Size, by Indication, 2017-2032 (USD Million)
TABLE 135. NATO Long-acting Somatostatin Analogues Market Size, by Neuroendocrine Tumors, 2017-2032 (USD Million)
TABLE 136. NATO Long-acting Somatostatin Analogues Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 137. NATO Long-acting Somatostatin Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 138. NATO Long-acting Somatostatin Analogues Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 139. Global Long-acting Somatostatin Analogues Market Size, by Country, 2017-2032 (USD Million)
TABLE 140. United States Long-acting Somatostatin Analogues Market Size, 2017-2032 (USD Million)
TABLE 141. United States Long-acting Somatostatin Analogues Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 142. United States Long-acting Somatostatin Analogues Market Size, by Indication, 2017-2032 (USD Million)
TABLE 143. United States Long-acting Somatostatin Analogues Market Size, by Neuroendocrine Tumors, 2017-2032 (USD Million)
TABLE 144. United States Long-acting Somatostatin Analogues Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 145. United States Long-acting Somatostatin Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 146. United States Long-acting Somatostatin Analogues Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 147. Canada Long-acting Somatostatin Analogues Market Size, 2017-2032 (USD Million)
TABLE 148. Canada Long-acting Somatostatin Analogues Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 149. Canada Long-acting Somatostatin Analogues Market Size, by Indication, 2017-2032 (USD Million)
TABLE 150. Canada Long-acting Somatostatin Analogues Market Size, by Neuroendocrine Tumors, 2017-2032 (USD Million)
TABLE 151. Canada Long-acting Somatostatin Analogues Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 152. Canada Long-acting Somatostatin Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 153. Canada Long-acting Somatostatin Analogues Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 154. Mexico Long-acting Somatostatin Analogues Market Size, 2017-2032 (USD Million)
TABLE 155. Mexico Long-acting Somatostatin Analogues Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 156. Mexico Long-acting Somatostatin Analogues Market Size, by Indication, 2017-2032 (USD Million)
TABLE 157. Mexico Long-acting Somatostatin Analogues Market Size, by Neuroendocrine Tumors, 2017-2032 (USD Million)
TABLE 158. Mexico Long-acting Somatostatin Analogues Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 159. Mexico Long-acting Somatostatin Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 160. Mexico Long-acting Somatostatin Analogues Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 161. Brazil Long-acting Somatostatin Analogues Market Size, 2017-2032 (USD Million)
TABLE 162. Brazil Long-acting Somatostatin Analogues Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 163. Brazil Long-acting Somatostatin Analogues Market Size, by Indication, 2017-2032 (USD Million)
TABLE 164. Brazil Long-acting Somatostatin Analogues Market Size, by Neuroendocrine Tumors, 2017-2032 (USD Million)
TABLE 165. Brazil Long-acting Somatostatin Analogues Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 166. Brazil Long-acting Somatostatin Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 167. Brazil Long-acting Somatostatin Analogues Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 168. United Kingdom Long-acting Somatostatin Analogues Market Size, 2017-2032 (USD Million)
TABLE 169. United Kingdom Long-acting Somatostatin Analogues Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 170. United Kingdom Long-acting Somatostatin Analogues Market Size, by Indication, 2017-2032 (USD Million)
TABLE 171. United Kingdom Long-acting Somatostatin Analogues Market Size, by Neuroendocrine Tumors, 2017-2032 (USD Million)
TABLE 172. United Kingdom Long-acting Somatostatin Analogues Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 173. United Kingdom Long-acting Somatostatin Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 174. United Kingdom Long-acting Somatostatin Analogues Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 175. Germany Long-acting Somatostatin Analogues Market Size, 2017-2032 (USD Million)
TABLE 176. Germany Long-acting Somatostatin Analogues Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 177. Germany Long-acting Somatostatin Analogues Market Size, by Indication, 2017-2032 (USD Million)
TABLE 178. Germany Long-acting Somatostatin Analogues Market Size, by Neuroendocrine Tumors, 2017-2032 (USD Million)
TABLE 179. Germany Long-acting Somatostatin Analogues Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 180. Germany Long-acting Somatostatin Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 181. Germany Long-acting Somatostatin Analogues Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 182. France Long-acting Somatostatin Analogues Market Size, 2017-2032 (USD Million)
TABLE 183. France Long-acting Somatostatin Analogues Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 184. France Long-acting Somatostatin Analogues Market Size, by Indication, 2017-2032 (USD Million)
TABLE 185. France Long-acting Somatostatin Analogues Market Size, by Neuroendocrine Tumors, 2017-2032 (USD Million)
TABLE 186. France Long-acting Somatostatin Analogues Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 187. France Long-acting Somatostatin Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 188. France Long-acting Somatostatin Analogues Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 189. Russia Long-acting Somatostatin Analogues Market Size, 2017-2032 (USD Million)
TABLE 190. Russia Long-acting Somatostatin Analogues Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 191. Russia Long-acting Somatostatin Analogues Market Size, by Indication, 2017-2032 (USD Million)
TABLE 192. Russia Long-acting Somatostatin Analogues Market Size, by Neuroendocrine Tumors, 2017-2032 (USD Million)
TABLE 193. Russia Long-acting Somatostatin Analogues Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 194. Russia Long-acting Somatostatin Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 195. Russia Long-acting Somatostatin Analogues Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 196. Italy Long-acting Somatostatin Analogues Market Size, 2017-2032 (USD Million)
TABLE 197. Italy Long-acting Somatostatin Analogues Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 198. Italy Long-acting Somatostatin Analogues Market Size, by Indication, 2017-2032 (USD Million)
TABLE 199. Italy Long-acting Somatostatin Analogues Market Size, by Neuroendocrine Tumors, 2017-2032 (USD Million)
TABLE 200. Italy Long-acting Somatostatin Analogues Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 201. Italy Long-acting Somatostatin Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 202. Italy Long-acting Somatostatin Analogues Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 203. Spain Long-acting Somatostatin Analogues Market Size, 2017-2032 (USD Million)
TABLE 204. Spain Long-acting Somatostatin Analogues Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 205. Spain Long-acting Somatostatin Analogues Market Size, by Indication, 2017-2032 (USD Million)
TABLE 206. Spain Long-acting Somatostatin Analogues Market Size, by Neuroendocrine Tumors, 2017-2032 (USD Million)
TABLE 207. Spain Long-acting Somatostatin Analogues Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 208. Spain Long-acting Somatostatin Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 209. Spain Long-acting Somatostatin Analogues Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 210. China Long-acting Somatostatin Analogues Market Size, 2017-2032 (USD Million)
TABLE 211. China Long-acting Somatostatin Analogues Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 212. China Long-acting Somatostatin Analogues Market Size, by Indication, 2017-2032 (USD Million)
TABLE 213. China Long-acting Somatostatin Analogues Market Size, by Neuroendocrine Tumors, 2017-2032 (USD Million)
TABLE 214. China Long-acting Somatostatin Analogues Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 215. China Long-acting Somatostatin Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 216. China Long-acting Somatostatin Analogues Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 217. India Long-acting Somatostatin Analogues Market Size, 2017-2032 (USD Million)
TABLE 218. India Long-acting Somatostatin Analogues Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 219. India Long-acting Somatostatin Analogues Market Size, by Indication, 2017-2032 (USD Million)
TABLE 220. India Long-acting Somatostatin Analogues Market Size, by Neuroendocrine Tumors, 2017-2032 (USD Million)
TABLE 221. India Long-acting Somatostatin Analogues Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 222. India Long-acting Somatostatin Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 223. India Long-acting Somatostatin Analogues Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 224. Japan Long-acting Somatostatin Analogues Market Size, 2017-2032 (USD Million)
TABLE 225. Japan Long-acting Somatostatin Analogues Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 226. Japan Long-acting Somatostatin Analogues Market Size, by Indication, 2017-2032 (USD Million)
TABLE 227. Japan Long-acting Somatostatin Analogues Market Size, by Neuroendocrine Tumors, 2017-2032 (USD Million)
TABLE 228. Japan Long-acting Somatostatin Analogues Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 229. Japan Long-acting Somatostatin Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 230. Japan Long-acting Somatostatin Analogues Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 231. Australia Long-acting Somatostatin Analogues Market Size, 2017-2032 (USD Million)
TABLE 232. Australia Long-acting Somatostatin Analogues Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 233. Australia Long-acting Somatostatin Analogues Market Size, by Indication, 2017-2032 (USD Million)
TABLE 234. Australia Long-acting Somatostatin Analogues Market Size, by Neuroendocrine Tumors, 2017-2032 (USD Million)
TABLE 235. Australia Long-acting Somatostatin Analogues Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 236. Australia Long-acting Somatostatin Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 237. Australia Long-acting Somatostatin Analogues Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 238. South Korea Long-acting Somatostatin Analogues Market Size, 2017-2032 (USD Million)
TABLE 239. South Korea Long-acting Somatostatin Analogues Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 240. South Korea Long-acting Somatostatin Analogues Market Size, by Indication, 2017-2032 (USD Million)
TABLE 241. South Korea Long-acting Somatostatin Analogues Market Size, by Neuroendocrine Tumors, 2017-2032 (USD Million)
TABLE 242. South Korea Long-acting Somatostatin Analogues Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 243. South Korea Long-acting Somatostatin Analogues Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 244. South Korea Long-acting Somatostatin Analogues Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 245. Global Long-acting Somatostatin Analogues Market Share, by Key Player, 2025
TABLE 246. Global Long-acting Somatostatin Analogues Market, Key Experts

Companies Mentioned

  • Amneal Pharmaceuticals, Inc.
  • Bachem Holding AG
  • BioSynthema Inc.
  • Camurus AB
  • Chengdu Tiantaishan Pharmaceutical Co., Ltd.
  • Chiasma, Inc.
  • Cipla Limited
  • Crinetics Pharmaceuticals, Inc.
  • Dauntless Pharmaceuticals, Inc.
  • Debiopharm Group
  • EVER Pharma GmbH
  • Ferring Pharmaceuticals
  • Ipsen Pharma
  • Midatech Pharma PLC
  • Mylan N.V.
  • Novartis AG
  • Peptron Inc.
  • Pfizer Inc.
  • Recordati S.p.A.
  • Sandoz International GmbH
  • ScinoPharm Taiwan Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Wockhardt Ltd.
  • Zydus Lifesciences Limited

Related Topics

Related Reports

Acromegaly Treatment Drugs Market Insights, Analysis and Forecast 2026-2031 - Product Image

Acromegaly Treatment Drugs Market Insights, Analysis and Forecast 2026-2031

  • Report
  • 89 Pages
  • Global
From
Carcinoid Syndrome - Market Insights, Epidemiology, and Market Forecast - 2034 - Product Image

Carcinoid Syndrome - Market Insights, Epidemiology, and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Manmade Version of Somatostatin Market - Global Forecast 2026-2032 - Product Image

Manmade Version of Somatostatin Market - Global Forecast 2026-2032

  • Report
  • 182 Pages
  • Global
From
Acromegaly - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Acromegaly - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 147 Pages
  • Global
From
Somatostatin Analogs Market - Global Forecast 2026-2032 - Product Image

Somatostatin Analogs Market - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.